Novo Nordisk Outlines Strategy 2030, Plan for Catalent Acquisition & Future Focus

Kasim Kutay, CEO of Novo Holdings, was recently interviewed by Bloomberg regarding the ongoing acquisition of Catalent, outlining Strategy 2030 and how they plan to reinvest cashflow and remain attractive to investors.

Whilst the acquisition of Catalent is ongoing and subject to regulatory approval, Kutay remains hopeful that the deal is approved so that Novo can utilize Catalent’s existing manufacturing capacity to improve production output. Regardless of whether the deal is approved, Novo continues to investigate ways in improving production capacity, focusing on the biopharma services sector and increasing green transition investments from 2 to 10%.

For more, please find the original source here.